DYAI logo

DYAI Dyadic International, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.32
-0.00 (-1.25%)

Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing…

Market Cap: $12.66Mwww.dyadic.com

Price

No data yet.

Social Signal Score

58
5d
—
30d
57
3 mentions
—
60d
57
3 mentions
—
90d
60
4 mentions
—
news: 4

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 1Hold 1Sell 0Strong Sell 0
Avg price target$3+849.4%
Low $3Median $3High $3
Current Consensus

Revenue

$449.1K-8.54%
$121.5K$733.5K$1.35M$1.96M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.23
$-0.27–$-0.18
1 analysts
FY2026
$-0.17
$-0.20–$-0.14
1 analysts
FY2027
$-0.12
$-0.14–$-0.10
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Mark A. Emalfarb
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
1.08
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-18.86
www.dyadic.com